22 June 2020

Boustead Holdings

Volatile Earnings Trend

By Raymond Choo Ping Khoon I pkchoo@kenanga.com.my

1QFY20 Core Net Loss (CNL) came in at RM73.1m. We deemed the results to be in line with our expectation. We are keeping our FY20 forecasts unchanged on expected volatile quarters ahead, with the group swinging back and forth between profitability and losses, judging by past quarterly trend. However, our target price is lowered from RM0.80 to RM0.66 in line with house's lower TP for Affin Holdings and Pharmaniaga. Maintain MP.

1QFY20 inline. 1QFY20 Core Net Loss (CNL) came in at RM73.1m, in line with our expectation. We are keeping our FY20 forecasts unchanged as the group is expected to continue seeing volatile quarters ahead based on near-term historical trend. No dividend was declared as expected.

Results' highlights. QoQ, 1QFY20 registered a narrower CNL of RM73.1m compared to net loss of RM205m in 4QFY19. The losses narrowed due to better performance from Pharmaceutical and Plantation which more than offset higher losses at Heavy industries and Trading. The Pharmaceutical division recorded a surplus of RM29.4m compared to a loss of RM240.5m in 4QFY19 bolstered by stronger demand from government and private hospitals in Malaysia and Indonesia. Similarly, Plantation return to profitability marginally due to higher palm product prices. The Trading, Finance & Investment division incurred a loss of RM22.4m compared to PBT of RM50.1m in 4QFY19 mainly due to stockholding losses recorded by Boustead Petroleum Marketing as a result of sharp drop in fuel prices.

YoY, 1QFY20 CNL widened no thanks to higher losses at Heavy Industries and Trading but cushioned by Pharmaceutical and Plantations. The Heavy Industries division losses widened to RM36.5m compared to RM18.2m in 1QFY19 due to loss from Boustead Naval Shipyard (BNS) and higher losses at Boustead Heavy Industries Corporation. Similarly, The Trading, Finance & Investment division recorded a deficit of RM22m against a surplus of RM79.3m in 1QFY19 due to lower average fuel prices. The loss incurred was mainly due to stockholding loss suffered by Boustead Petroleum Marketing as a result of sharp drop in fuel price as well as lower sales volume during MCO period. The Plantation division registered an improved result with a PBT of RM1.3m against the loss before tax of RM14m in 1QFY19. This was mainly attributed to better palm products prices. FFB production for the quarter of 209,857 MT was 19% lower than 1QFY19 crop of 258,996 MT. Oil extraction and kernel extraction rates were also lower at 21.0% (1QFY19: 21.4%) and 4.3% (1QFY19: 4.5%) respectively. The Pharmaceutical division's PBT rose 14% due to stronger contribution from Governments hospital and lower operating costs.

Outlook. The group is expected to continue seeing volatile quarterly results based on its historical volatile earnings trend. All in, we expect the trading and manufacturing as well as pharmaceutical divisions to show pedestrian growth but deliver sustainable recurring incomes. Meanwhile, plantation earnings rely on CPO movement since 91% of its plantation estates are already matured of which the outlook over the short-term looks cloudy. The Heavy Industries division remains volatile with quarterly earnings oscillating between profits and losses.

Maintain MP. Our target price is lowered from RM0.80 to RM0.66 after imputing a 20% holding co discount and lower TP for both Affin Holdings and Pharmaniaga in line with our house's TPs. That said, downside to the share price may be limited by a yet to be finalised reported proposal that LTAT plans on taking Boustead private at RM0.80/share.

MARKET PERFORM ↔

Price : RM0.66
Target Price : RM0.66 ↓



KLCI	1,507.26
YTD KLCI chg	-5.1%
YTD stock price chg	-30.5%

Stock Information

Shariah Compliant	Yes
Bloomberg Ticker	BOUS MK Equity
Market Cap (RM m)	1,337.8
Shares Outstanding	2,027.0
52-week range (H)	1.26
52-week range (L)	0.35
3-mth avg daily vol:	9,277,943
Free Float	20%
Beta	1.4

Major Shareholders

Lembaga Tabung Angkatan Tentera	59.5%
KWAP	9.2%
Employees Provident Fund	5.0%

Summary Earnings Table

FY Dec (RM m)	2019A	2020E	2021E
Turnover	10,334	10,556	10,748
PBT	(1,336)	(131.3)	(134.8)
Net Profit (NP)	(1,279)	(46.6)	(50.7)
Core Net Profit/Loss	(198.0)	(46.6)	(50.7)
Earnings Revision	-	-	-
Core EPS/(LPS) (sen)	(9.8)	(2.3)	(2.5)
EPS growth (%)	NM	(76.5)	8.7
NDPS (sen)	0.0	0.0	0.0
BV/Share (RM)	1.85	1.79	1.74
PER (X)	NM	NM	NM
P/BV (X)	0.4	0.4	0.4
Net Gearing (x)	1.9	2.6	3.5
Dividend Yield (%)	0.0	0.0	0.0

kenanga

22 June 2020

Result Highlight (Q-o-Q)					
FY Dec (RM m)	1QFY19	4QFY19	1QFY20	Y-o-Y chg (%)	Q-o-Q chg (%)
Revenue	2,506.7	2,536.2	2,260.9	(10.9)	(9.8)
Plantation	134.9	179.1	162.7	(9.2)	20.6
Heavy Industries	207.5	179.4	86.2	(52.0)	(58.5)
Property & Industrial	200.6	193.2	166.6	(13.8)	(16.9)
Pharmaceutical	786.1	715.7	819.9	14.6	4.3
Trading, Finance & Invest	1,177.6	1,268.8	1,025.5	(19.2)	(12.9)
Pre-tax profit / (loss)	51.5	(1,349.8)	(53.3)	(96.1)	(203.5)
Plantation	(14.0)	(177.7)	1.3	(100.7)	(109.3)
Heavy Industries	(18.2)	(1,013.8)	(36.5)	(96.4)	100.5
Property & Industrial	(21.5)	32.1	(25.1)	(178.2)	16.7
Pharmaceutical	25.9	(240.5)	29.4	(112.2)	13.5
Trading, Finance & Invest	79.3	50.1	(22.4)	(144.7)	(128.2)
Associates	27.1	102.1	18.7	(81.7)	(30.9)
Pretax profit / (loss)	51.5	(1349.8)	(53.3)	(96.1)	(203.5)
Taxation	-40.1	55.5	(22.3)	(140.2)	(44.4)
Minorities^	(33.8)	168.6	2.5	(98.5)	(107.4)
Reported Net profit / (loss)	(22.4)	(1,125.7)	(73.1)	(93.5)	(226.3)
Core Net Loss (CNL)	(22.4)	(205)	(73.1)	(64.4)	(226.3)
EPS / (LPS)	(1.1)	(55.5)	(3.6)	(93.5)	224.3
Pre-tax margin (%)					
Plantation	(10.4)	(99.2)	0.8		
Heavy Industries	(8.8)	(565.1)	(42.3)		
Property & Industrial	(10.7)	16.6	(15.1)		
Pharmaceutical	3.3	(33.6)	3.6		
Trading, Finance & Invest	6.7	3.9	(2.2)		
Effective tax rate	77.9	4.1	(41.8)		
Source: Bursa Malaysia, Ker	nanga Research				

Sum-of-parts valuation Listed entities	no. of shares	Current share	Value (RM m)	Comments
	effective stakes (m)	price (RM/share)	raido (ruir iii)	
Affin Holdings	309.2	1.45	448	Based on hous target price
Boustead Heavy Industries	161.5	1.60	258	g p
Boustead Plantations	128.8	1.00	1,286	
Pharmaniaga	309.2	1.85	174	Based on hous target price
Property development	Remaining land bank (acres)	Market value psf (RM)	Market Value (RM m)	
Mutiara Rini (Johor)	980	30	1,281	
Mutiara Damansara	24	200	209	
Mutiara Hills Semenyih	125	25	136	
Bukit Raja (30% stake)	500	30	196	
Jalan Chochrane			118	
Bukit Rajah (Astacanggih)			160	
Property investments	Net lettable	Market value	Value (RM m)	
0	area (NLA)	psf (RM)	E04	
Curve	680,000	850	561	
e@Curve Curve NX	200,000 80,000	850 800	170 74	
Menara Boustead KL & Wisma Boustead	277,174	700	195	
Menara Affin	200,756	700	140	
Menara Boustead Penang	210,083	350	74	
Menara UAC	210,000	000	45	
183 Jalan Ampang			142	
Hotels	No of rooms	Estimated		
		average price/room (RM)		
Royale Bintang Kuala Lumpur	400	400,000	160	
Royale Bintang Curve	150	300,000	45	
Royale Bintang Seremban	300	100,000	30	
Royale Bintang Damansara	370	250,000	93	
Trading and manufacturing (excl UAC)		1,220	Based on 12x earnings	
Indonesian listed (PT Millenium		12	Based on market	
Pharmacon International TBK)		·-	price and 55% stake	
Less net debt			(5,545)	
			1,681	
Total RNAV less net debt no. of shares			2,027	

Source: Company, Bursa Malaysia, Bloomberg, Kenanga Research

22 June 2020

Stock Ratings are defined as follows:

Stock Recommendations

OUTPERFORM : A particular stock's Expected Total Return is MORE than 10%

MARKET PERFORM : A particular stock's Expected Total Return is WITHIN the range of -5% to 10%

UNDERPERFORM : A particular stock's Expected Total Return is LESS than -5%

Sector Recommendations***

OVERWEIGHT : A particular sector's Expected Total Return is MORE than 10%

NEUTRAL : A particular sector's Expected Total Return is WITHIN the range of -5% to 10%

UNDERWEIGHT : A particular sector's Expected Total Return is LESS than -5%

***Sector recommendations are defined based on market capitalisation weighted average expected total return for stocks under our coverage.

This document has been prepared for general circulation based on information obtained from sources believed to be reliable but we do not make any representations as to its accuracy or completeness. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may read this document. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees. Kenanga Investment Bank Berhad accepts no liability whatsoever for any direct or consequential loss arising from any use of this document or any solicitations of an offer to buy or sell any securities. Kenanga Investment Bank Berhad and its associates, their directors, and/or employees may have positions in, and may effect transactions in securities mentioned herein from time to time in the open market or otherwise, and may receive brokerage fees or act as principal or agent in dealings with respect to these companies.

Published and printed by:

KENANGA INVESTMENT BANK BERHAD (15678-H)

Level 17, Kenanga Tower, 237, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia

Telephone: (603) 2172 0880 Website: www.kenanga.com.my E-mail: research@kenanga.com.my

